Dimopoulos Johannes C A, Kirisits Christian, Petric Primoz, Georg Petra, Lang Stefan, Berger Daniel, Pötter Richard
Department of Radiotherapy and Radiobiology, Medical University of Vienna, Vienna, Austria.
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):83-90. doi: 10.1016/j.ijrobp.2006.04.041. Epub 2006 Jul 12.
The aims of this study were to investigate the clinical feasibility and to report on preliminary treatment outcomes of combined intracavitary/interstitial brachytherapy, using a novel applicator and magnetic resonance imaging (MRI)-based treatment planning in patients with locally advanced cervical cancer.
A total of 22 cervical cancer patients with insufficient response and/or unfavorable topography after external-beam irradiation were included in this study. Parametrial extent of the disease in these patients was judged to exceed the coverage limit of intracavitary brachytherapy alone. A modified tandem/ring (T/R) applicator for guidance of parametrial needles (N) was used to perform high-dose-rate-brachytherapy with MRI-based treatment planning. Clinical feasibility and preliminary treatment outcomes were assessed.
A total of 44 interstitial needle implants were performed. The spatial relations between the T/R + N applicator, high-risk clinical target volume, and organs at risk were visible clearly in all cases. Accurate and reproducible needle placement could be achieved in the majority of cases. No severe adverse events were caused by the intervention. The mean follow-up period was 20 months (range, 5-35 months). No G3 to G4 early or persistent late side effects were observed. Complete remission was achieved in 21 patients (95%). One local recurrence was observed within the high-risk clinical target volume area during follow-up.
Our preliminary clinical experience indicates that combined intracavitary and interstitial MRI-based brachytherapy in patients with significant residual disease after external-beam therapy extending up to the distal third of parametria is feasible and allows excellent local control and a low rate of morbidity.
本研究旨在探讨联合腔内/组织间近距离放射治疗的临床可行性,并报告使用新型施源器和基于磁共振成像(MRI)的治疗计划对局部晚期宫颈癌患者进行初步治疗的结果。
本研究共纳入22例在体外照射后反应不足和/或局部解剖结构不佳的宫颈癌患者。这些患者的宫旁病变范围被判定超过单纯腔内近距离放射治疗的覆盖范围。使用一种改良的串联/环形(T/R)施源器来引导宫旁针(N),并基于MRI的治疗计划进行高剂量率近距离放射治疗。评估临床可行性和初步治疗结果。
共进行了44次组织间针植入。在所有病例中,T/R + N施源器、高危临床靶区和危及器官之间的空间关系均清晰可见。在大多数病例中能够实现准确且可重复的针放置。干预未引起严重不良事件。平均随访期为20个月(范围5 - 35个月)。未观察到3级至4级早期或持续性晚期副作用。21例患者(95%)实现完全缓解。随访期间在高危临床靶区内观察到1例局部复发。
我们的初步临床经验表明,对于体外照射后残留病变显著且累及宫旁远端三分之一的患者,联合基于MRI的腔内和组织间近距离放射治疗是可行的,并且能实现良好的局部控制和低发病率。